BRIEF-Corcept Therapeutics Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1c

Reuters

24 Jun

BRIEF-Corcept <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1c

June 23 (Reuters) - Corcept Therapeutics Inc CORT.O:

CORCEPT PRESENTS DATA FROM TREATMENT PHASE OF CATALYST TRIAL AT AMERICAN DIABETES ASSOCIATION’S 85TH SCIENTIFIC SESSIONS WITH SIMULTANEOUS PUBLICATION IN DIABETES CARE
CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN HBA1C
CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS SECONDARY ENDPOINTS WITH REDUCED BODY WEIGHT AND WAIST CIRCUMFERENCE

Source text: ID:nBw7PP9vfa

Further company coverage: CORT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2545144012"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545144012\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545144012?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 04:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545144012","market":"us","top_or_hot":-1,"title":"BRIEF-Corcept Therapeutics Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1c","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1c</title></head><body><p><span>June 23 (Reuters)</span><span> - </span>Corcept Therapeutics Inc <span>CORT.O</span>:</p><ul><li><p>CORCEPT PRESENTS DATA FROM TREATMENT PHASE OF CATALYST TRIAL AT AMERICAN DIABETES ASSOCIATION’S 85TH SCIENTIFIC SESSIONS WITH SIMULTANEOUS PUBLICATION IN DIABETES CARE</p></li><li><p>CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN HBA1C</p></li><li><p>CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS SECONDARY ENDPOINTS WITH REDUCED BODY WEIGHT AND WAIST CIRCUMFERENCE</p></li></ul><p>Source text: <span>ID:nBw7PP9vfa</span></p><p>Further company coverage: <span>CORT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Corcept Therapeutics Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1c</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Corcept Therapeutics Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1c\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-24 04:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Corcept <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1c</title></head><body><p><span>June 23 (Reuters)</span><span> - </span>Corcept Therapeutics Inc <span>CORT.O</span>:</p><ul><li><p>CORCEPT PRESENTS DATA FROM TREATMENT PHASE OF CATALYST TRIAL AT AMERICAN DIABETES ASSOCIATION’S 85TH SCIENTIFIC SESSIONS WITH SIMULTANEOUS PUBLICATION IN DIABETES CARE</p></li><li><p>CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN HBA1C</p></li><li><p>CORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS SECONDARY ENDPOINTS WITH REDUCED BODY WEIGHT AND WAIST CIRCUMFERENCE</p></li></ul><p>Source text: <span>ID:nBw7PP9vfa</span></p><p>Further company coverage: <span>CORT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nTUA8JCDZF:1","article_id":"2545144012","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545144012","pubTimestamp":1750712283,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Corcept Therapeutics Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1cJune 23 (Reuters) - Corcept Therapeutics Inc CORT.O:CORCEPT PRESENTS DATA FROM TREATMENT PHAS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU0566484027.USD":"安本美国小盘成长股","BK4532":"文艺复兴科技持仓","CORT":"Corcept医疗","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H"},"translate_title":"简介-Corcept Therapeutics表示CATALYST试验达到了主要终点，HbA1c显着改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":0.9},"content_text":"BRIEF-Corcept Therapeutics Says CATALYST Trial Meets Primary Endpoint With Significant Improvement In HbA1cJune 23 (Reuters) - Corcept Therapeutics Inc CORT.O:CORCEPT PRESENTS DATA FROM TREATMENT PHASE OF CATALYST TRIAL AT AMERICAN DIABETES ASSOCIATION’S 85TH SCIENTIFIC SESSIONS WITH SIMULTANEOUS PUBLICATION IN DIABETES CARECORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT IN HBA1CCORCEPT THERAPEUTICS INC - CATALYST TRIAL MEETS SECONDARY ENDPOINTS WITH REDUCED BODY WEIGHT AND WAIST CIRCUMFERENCESource text: ID:nBw7PP9vfaFurther company coverage: CORT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}